Phase II Study of Multimodal Ablation Combined With Drug Therapy for Liver Metastases from Colorectal Cancer, Triple-Negative Breast Cancer, and Melanoma

What this Trial Is About

Researchers are studying the treatment of liver metastases from colorectal cancer, triple-negative breast cancer, and melanoma, focusing on the combination of multimodal thermophysical ablation therapy with immunotherapeutic drugs like pucotenlimab. This Phase II clinical trial aims to explore the effectiveness and safety of this combination therapy, hoping to overcome current limitations in treating liver metastases from these solid tumors. Participants will receive multimodal tumor thermal therapy combined with systemic drug treatments tailored to each cancer type. The colorectal cancer group receives ablation with cadonilimab and fruquintinib the triple-negative breast cancer group receives ablation with pucotenlimab plus chemotherapy agents such as TPC or sacituzumab govitecan, eribulin, gemcitabine, or UTD1 and the melanoma group receives ablation with pembrolizumab or toripalimab alongside other agents based on first-line treatment and melanoma subtype. During the study, participants will be closely monitored for treatment response and safety for up to two years. Researchers will assess outcomes including objective response rate, disease control rate, duration of response, progression-free survival, overall survival, and tolerability. Participants undergo evaluations such as lab tests to confirm organ function and performance status, with follow-up visits to measure treatment effects and monitor health throughout the study period.

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.